These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35790094)

  • 1. Acyl-Hydrazide Derivatives of a Xanthine Carboxylic Congener (XCC) as Selective Antagonists at Human A
    Kim YC; Karton Y; Ji XD; Melman N; Linden J; Jacobson KA
    Drug Dev Res; 1999 Aug; 47(4):178-188. PubMed ID: 35790094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A
    Jacobson KA; IJzerman AP; Linden J
    Drug Dev Res; 1999 May; 47(1):45-53. PubMed ID: 38239816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
    Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
    J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
    Kim SA; Marshall MA; Melman N; Kim HS; Müller CE; Linden J; Jacobson KA
    J Med Chem; 2002 May; 45(11):2131-8. PubMed ID: 12014951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
    Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA
    J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing Adenosine and P2 Receptors: Design of Novel Purines and Nonpurines as Selective Ligands.
    Jacobson KA
    Drug Dev Res; 2001; 52(1-2):178-186. PubMed ID: 38239932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
    Li AH; Moro S; Melman N; Ji XD; Jacobson KA
    J Med Chem; 1998 Aug; 41(17):3186-201. PubMed ID: 9703464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.
    Ji XD; Jacobson KA
    Drug Des Discov; 1999 Nov; 16(3):217-26. PubMed ID: 10624567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine.
    Urmaliya VB; Church JE; Coupar IM; Rose'Meyer RB; Pouton CW; White PJ
    J Cardiovasc Pharmacol; 2009 May; 53(5):424-33. PubMed ID: 19333129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.
    Kim YC; Ji X; Melman N; Linden J; Jacobson KA
    J Med Chem; 2000 Mar; 43(6):1165-72. PubMed ID: 10737749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New substituted 9-alkylpurines as adenosine receptor ligands.
    Camaioni E; Costanzi S; Vittori S; Volpini R; Klotz KN; Cristalli G
    Bioorg Med Chem; 1998 May; 6(5):523-33. PubMed ID: 9629466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyran Template Approach to the Design of Novel A
    Li AH; Ji XD; Kim HS; Melman N; Jacobson KA
    Drug Dev Res; 1999 Dec; 48(4):171-177. PubMed ID: 27182099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.
    Jiang J; van Rhee AM; Chang L; Patchornik A; Ji XD; Evans P; Melman N; Jacobson KA
    J Med Chem; 1997 Aug; 40(16):2596-608. PubMed ID: 9258367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists.
    Jiang JL; van Rhee AM; Melman N; Ji XD; Jacobson KA
    J Med Chem; 1996 Nov; 39(23):4667-75. PubMed ID: 8917655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.
    Ji X; Kim YC; Ahern DG; Linden J; Jacobson KA
    Biochem Pharmacol; 2001 Mar; 61(6):657-63. PubMed ID: 11266650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors.
    Gessi S; Varani K; Merighi S; Leung E; Mac Lennan S; Baraldi PG; Borea PA
    Purinergic Signal; 2006 Nov; 2(4):583-8. PubMed ID: 18404460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A
    Jacobson KA; Moro S; Kim YC; Li AH
    Drug Dev Res; 1998; 45(3-4):113-124. PubMed ID: 31808655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.
    Kim HO; Ji XD; Melman N; Olah ME; Stiles GL; Jacobson KA
    J Med Chem; 1994 Nov; 37(23):4020-30. PubMed ID: 7966162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
    Ongini E; Dionisotti S; Gessi S; Irenius E; Fredholm BB
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):7-10. PubMed ID: 9933143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.